CD14 and melanoma: In melanoma patients, it has been shown that untreated patients with untreated metastatic disease have decreased CD14+ monocytes in the peripheral blood compared to healthy controls, a finding recapitulated in our analysis, and that the phenotypes of these monocytes may be a predictor of disease response to CBI [22].